Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

NCT05432167 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05432167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05432167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
April 29, 2022
Completion date
May 2, 2024
Enrollment
195 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases, uncontrolled hypertension